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Chronic Disease Data And Analysis: Current State Of the Field

Lisa M. Sullivan
Boston University

Ralph D’Agostino, Sr.
Boston University

Chronic disease usually spans years of a person’s lifetime and includes a disease free period, a preclinical, or
latent period, where there are few overt signs of disease, a clinical period where the disease manifests and is
eventually diagnosed, and a follow-up period where the disease might progress steadily or remain stable. It is
often of interest to investigate the relationship between risk factors measured at a point in time (usually during the
disease free or preclinical period), and the development of disease at some future point (e.g., 10 years later). We
outline some popular designs for the identification of subjects and discuss issues in measurement of risk factors
for analysis of chronic disease. We discuss some of the complexities in these analyses, including the time
dependent nature of the risk factors and missing data issues. We then describe some popular statistical modeling
techniques and outline the situations in which each is appropriate. We conclude with some speculation toward
future development in the area of chronic disease data and analysis.
Keywords: Chronic disease, cardiovascular disease, Framingham Heart Study, logistic regression analysis,
longitudinal data, missing data, mixed models, survival analysis

Introduction
A chronic disease is a disease first characterized
by a development period or latent period in
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which the disease progresses subclinically. The
latent period can be extensive in time. For
example, in cardiovascular disease, build up of
plaque in the arteries can begin in childhood.
During this latent period the person often
displays no overt effects or problems. Then the
disease manifests itself in a clinical phase.
With cardiovascular disease, this may
begin with a myocardial infarction (heart attack)
where the heart suffers permanent injury due to
the blockage caused by the plaque. After the
appearance of the clinical phase, the affected
person (or host) may follow a course that leads
to little or substantial deterioration and possibly
death.
In this example of cardiovascular
disease, the clinical phase is initiated by a
clinical event, a heart attack, and then followed
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by a post event phase where there may be a
general weakening of the body which increases
the risk of subsequent cardiovascular events
such as a second heart attack or a stroke
resulting in death.
Lung cancer is an example of another
chronic disease. Here the subclinical, latent
period can consist of lung tumors developing
over a period of more than 10 years before
clinical manifestation and diagnosis. After
diagnosis, there can be periods of stabilization,
remission and progression.
AIDS is still
another example, where the subclinical stage
can be characterized by a positive HIV
infection. The clincal manifestation of AIDS

may then appear followed by a series of
infections,
increased
deterioration
and
ultimately death. Alzheimer’s disease provides
an example where the distinction between the
preclinical stage and clinical stage is blurred. In
the preclinical phase, there is a progressive
decline in cognitive function, especially noted in
short term memory, and often personality
changes. These ultimately lead to a stage where
the person is unable to care for him or herself.
The diagnosis of Alzheimer’s disease often
results when the person is debilitated and other
forms of dementia (e.g., caused by a series of
strokes) are ruled out.

A simple model for chronic disease is as follows:
Disease Free

Preclinical (Latent Period)

Interest focuses on all four components. Each
presents detailed and sophisticated modeling,
data collection and analytic issues. Consider,
for example, the ‘Disease Free -> Preclinical
(Latent Period) -> Clinical Manifestation’
DF

PC

(1)
Clinical Manifestation

Follow-Up

component. This can be further refined to three
submodels (shown below) where DF represents
a completely disease-free state, PC represents
preclinical signs and symptoms and C
represents disease manifestation (clincal):
C

(2.1)

PC2

C

(2.2)

PC

C

(2.3)

PC1
DF
DF

In (2.1), the disease free (DF) stage leads to the
preclinical (PC) stage which in turn leads
directly to the clinical stage (C). In such a
situation knowledge of the preclinical stage
could be useful in delaying or averting the
clincal stage (C). Simple models of breast and
colon cancer fit this situation. In (2.2), the
disease free (DF) stage can lead to preclinical
stages 1 or 2 (PC1 and PC2, respectively). PC1
does not progress to the clinical stage (C) while
PC2 does. In this situation, identification of the

preclinical stage (PC) does not imply that the
clincal stage (C) follows. Cervical cancer is an
example of this situation. Lastly, (2.3) displays
a situation where the preclinical stage (PC) may
actually revert to the completely disease free
(DF) stage or may lead to the clinical (C) stage.
We could extend and elaborate the
second component of model (1) ‘Clinical
Manifestation -> Follow-Up’ in a similar
fashion incorporating the complexities that are
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involved in diagnosing the presence of the
disease and the follow-up after that.
Chronic disease data and analysis
questions relate to all aspects of the above
(disease free, preclinical, clinical manifestation
and follow-up). Good statistical approaches
involve hypothesizing models for these aspects,
collecting appropriate data, and then fitting and
testing the appropriate models. Before fitting
statistical models, biological models need to be
Risk Factors
Age
Gender
Smoking Status
Systolic Blood Pressure
Total Cholesterol

To turn this into a statistical model one
needs to decide how to identify appropriate
(disease free) subjects, how many subjects to
sample, when to measure the risk factors and
how long to follow them. The latter item of
follow-up is to ensure that a sufficient number
develop a myocardial infarction so the
components (or parameters) of the mathematical
model can be estimated with good precision.
In a later part of this article we discuss
in more detail the methods of statistical
modeling for chronic disease. We discuss some
popular designs for studies of chronic disease
and we use cardiovascular disease as an
example throughout the discussion. We review
some of the methodologic issues that arise in
studies of chronic disease and outline some
popular statistical modeling and analysis
techniques. We conclude with some speculation
towards future developments. In the next section
we present an example to motivate the
discussion that follows.
2. Motivation: Cardiovascular Disease Example
Consider a study of cardiovascular
disease, in particular a study of the risk factors
associated
with
the
development
of
cardiovascular disease. A first challenge is to
understand the outcome, and in particular the
conditions that should be considered part of the
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formulated. Both (1) and (2) above represent
simple models.
One important set of models relate risk
factors (RF) of a disease free individual to the
probability of manifestation of the clinical stage
of the disease. For example, the relationship
between age, gender, smoking status, blood
pressure and cholesterol to the development of a
myocardial infarction could be modelled as:

Clinical Manifestation
Myocardial Infarction

(3)

outcome and how they should be measured. A
second challenge is to determine which risk
factors should be measured and how frequently
they should be measured in the study subjects.
A related challenge is the specification of the
appropriate statistical model to relate candidate
risk factors to the outcome. In the following we
illustrate the complexities of each step using
cardiovascular disease as an example.
Defining the Outcome. Cardiovascular
disease includes a number of conditions and is a
major cause of morbidity and mortality
worldwide. The most common serious
cardiovascular disease is coronary heart disease
(also called cardiac ischemia, defined as
insufficient blood supply due to atherosclerosis
of the coronary arteries). It consists of
myocardial infarction (heart attack), which is
direct damage to the heart, coronary deaths, and
angina (persistent chest pain due to cardiac
ischemia). Cardiovascular disease also includes
other conditions such as stroke (or brain attack),
and peripheral artery disease (circulation
problems often in the calves). Cardiovascular
disease is believed to have a long preclinical or
latent stage.
For example, patients with coronary
heart disease (CHD) are diagnosed (and enter
the clinical stage) in a variety of ways. One
patient may present with angina at an early
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stage while another may suffer a heart attack
after an otherwise asymptomatic history.
Accurate determination of a cardiovascular
event is critical, and the technologies to
determine specific events are evolving over
time. At one time an MI was mainly diagnosed
by electocardiogram. Now it is standard to use
enzyme tests (e.g., SGOT and CPK) Often
chronic disease outcomes include conditionspecific mortality (e.g., death due to
cardiovascular disease). In such cases, elaborate
protocols are required to ascertain outcome
status. These include, in some cases, reviewing
death certificates and/or hospital records.
Determining cause of death can be further
complicated by incomplete or ambiguous
specification of the cause of death by the
medical personnel evaluating the death.
Specifying the Risk Factors and the
Data Collection Schedule. Determining the risk
factors associated with the development of
chronic disease (e.g., cardiovascular disease)
requires an understanding of the biological
complexity of the disease, some of which might
change over time. Generally, studies of
cardiovascular disease consider the following
risk factors: gender, age, blood pressure,
cholesterol, smoking status, and history of
diabetes. Cardiovascular diseases span decades
of individuals lives (from the preclinical to the
clinical and follow-up stages).
Studies of cardiovascular disease often
take years to complete, with the duration of the
study influenced by the time it takes to observe
a sufficient number of outcome events. The
importance and influence of risk factors may
vary over time (e.g., obesity at an early age and
maintained over time may be important in
leading to cardiovascular disease while the most
recent blood pressure may be more important
than blood pressure measured decades earlier).
So, often risk factors are measured at the outset,
and then repeated over the follow-up period.
Investigators must decide what intervals are
most appropriate to obtain repeat measurements.
The interval is influenced by the stability (or
lack of) of the risk factors over time.
For example, total cholesterol level is a
relatively stable risk factor whereas smoking
status is not. The latter would need to be
measured on a more frequent basis. In recent

studies of cardiovascular disease, investigators
consider genetic and environmental factors,
along with a broader array of clinical risk
factors. In some cases, investigators have the
flexibility to add new risk factors to a data
collection protocol during an ongoing study.
This introduces an analytic issue in that these
new risk factors will not be measured on the
same schedule as the core set (i.e. those
measured since the outset). In cardiovascular
disease, surgical procedures have also advanced
rapidly in the last two decades and include
introduction of artificial aortic valves, open
heart surgery, angioplasty (opening blocked
arteries using balloon catheters) and regulation
of heart rythms by implanted pacemakers.
In parallel, pharmacologic treatments
have become increasingly effective in treating
known risk factors of cardiovascular disease
(e.g., hypertension, hyperlipidemia) thereby
slowing the manifestation and progression of
disease. It is important to measure these
interventions, which generally modify the
effects of the risk factors on the development of
disease, along with the risk factors themselves.
Designs for studies of chronic disease and
methologic issues that arise in studies of chronic
disease are discussed in detail in Section 3.
Choosing the Correct Model. The
choice of the appropriate statistical model
should be based primarily on a biological
model. It should also be influenced by specific
aspects of the design such as whether subjects
are followed for a fixed period of time and then
determined to have or not have the disease at the
end of the observation period or whether
subjects are followed for different amounts of
time and have disease status ascertained at the
end of the observation period. In a study of
cardiovascular disease, a subject might die
during the observation period due to cancer (or
some disease other than cardiovascular disease)
and at the time of death be free of
cardiovascular disease. The most appropriate
statistical model is one that utilizes all of the
information that was measured on this person
rather than exclude him or her because of the
complexity of the data. Popular statistical
models for studies of chronic disease are
discussed in detail in Section 4.

CHRONIC DISEASE DATA AND ANALYSIS
3. Designs, Subject Selection and Data for
Studies of Chronic Disease
The data for studies of the relationship
between risk factors and development and
progression of chronic disease can be
prospective, retrospective or cross-sectional.
Prospective study designs involve identifying
individuals who are free of the disease of
interest and following them over time. These
studies can include repeated measurements of
risk factors over time and monitoring for the
development and progression of disease. The
schedule for following individuals and repeating
measurements depends on a number of factors
including the stability of the risk factors over
time and the nature of the relationship between
the risk factors and disease status over time.
Retrospective studies (also called case control
studies) usually involve identifying two groups
of individuals; those with the disease of interest
(often called cases) and matches who are free of
the disease of interest (often called controls).
Data are collected retrospectively usually
by way of individual’s recollection of prior
health and risk behaviors or through medical
record review. These studies are not optimal. It
is usually difficult to assemble representative
groups of cases and controls. Often the cases
represent either the sickest (e.g., subjects
enrolled through an Alzheimer’s clinic) or the
healthiest (e.g., those who have not died) of
those affected with the disease. Further, the
controls often differ in many ways from the
cases, confounding the comparison of cases and
controls. In addition, these studies can be
subject to a number of biases (for example,
recall bias or inaccurate recollection of specific
behaviors or measurment based on incomplete
medical records).
Cross-sectional studies are conducted at a
point in time and represent concurrent risk
factor and disease status. In some crosssectional studies, individuals provide historical
data on risk behaviors on the basis of
recollection, thereby also subjecting these
studies to recall bias.
Longitudinal cohort studies are most well
suited for the analysis of chronic disease. We
now describe in detail the specifics of
longitudinal cohort studies and outline a well
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known study of cardiovascular disease, the
Framingham Heart Study.
3.1. Longitudinal Cohort Studies: The
Framingham Heart Study
In longitudinal cohort studies, a group or
cohort of individuals is assembled at the outset.
The inclusion criteria often require a set of
individuals to be free of the disease of interest.
This is not always the case and those with
prevalent disease may be enrolled at the outset.
Individuals are followed prospectively in time.
Serial measurements can be taken on a
predetermined schedule, often at fixed time
intervals (e.g., measurements every 2 years or
every 5 years). Outcome or disease status is
measured over time. For those individuals who
develop disease, measures of the progression or
severity of disease are also taken. There are
several, large longitudinal cohort studies of
cardiovascular disease, probably the best known
study is the Framingham Heart Study, described
below.
The Framingham Heart Study began in
1948 and is one of the most ambitious and
daring longitudinal medical studies ever
initiated. A cohort of 5,209 individuals, 2336
males and 2873 females, was enrolled from
Framingham, MA. These represented a 60%
sample of the town with ages from 28 to 62
years. Multiple risk factors were measured
biennially, and the study continues today with
surviving participants involved for over 50
years. Major cardiovascular risk factors have
been measured since the outset (e.g., blood
pressure, total cholesterol and smoking status)
while others have been introduced as they were
hypothesized to have an impact on the
develoment of cardiovascular disease (e.g.,
HDL
cholesterol,
LDL
cholesterol,
homocystene and fibrinogen). Development of
cardiovascular events is recorded over time
including coronary heart disease (and its
components; myocardial infarction, coronary
death and angina), stroke, intermittent
claudication (a peripheral arterial disease),
congestive heart failure and cardiovascular
disease death. Intense efforts continue to be
utilized to gather complete information on every
subject. There are some missing data due to
subjects moving from the area or discontinuing
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participation (which is minimal). The total loss
to follow-up is less than 3 percent. The
Framingham Heart Study was expanded in 1971
to include a cohort of the offspring of the
original participants and their spouses. These
data allow for an investigation of the evolution
of new detection technologies such as
echocardiogram and carotid ultrasound and the
study of the effects of genetics on development
of cardiovascular and other chronic diseases
such as dementia.
3.2. Methodological Issues in Chronic Disease
Studies
There are a number of major methodologic
issues that arise in longitudinal studies, two are
discussed here. The first issue is based on
changing definitions of risk factors and
outcomes over time. For example, technological
advances have resulted in better diagnostic tests
for determining the presence or absence of
chronic disease. Studies utilizing better
diagnostic tests might observe more outcome
events and possible different relationships
between risk factors and disease. In some
chronic diseases (e.g., diabetes) medical
specialists have revised the clinical criteria for
diagnosing an individual (e.g., different
threshold criteria on laboratory tests).
Even the definition of myocardial infarction
has chenged over time. In the late 1940s, its
determination
was based
mainly
on
electrocardiogram. Later, enzyme tests, SGOT
and CPK, became standard components of the
definition of myocardial infarction starting in
the mid 1950s and proceeding during the 1960s.
In other areas, more sensitive assays have been
developed over time for measuring risk factors
(e.g., HDL and LDL cholesterol). As
modifications occur during a study, analysts
must take steps to make the data as comparable
over time as possible. The same applies when
making comparisons to external studies, these
may have employed different definitions and
assays.
A second methodological issue in
longitudinal studies concerns missing data.
Even when intensive surveillance programs are
in place, such as those used in the Framingham
Heart Study, there are often situations where
complete data is not gathered on every subject.

In longitudinal studies of chronic disease, there
are instances where data are missing because
subjects fail to show up at scheduled
examinations, fail to complete certain
assessments even when attending the
examination, or drop out during the course of
the study. These circumstances produce unequal
numbers of repeated measurements on different
individuals. There are several approaches for
performing analysis in the presence of missing
data.
First, analysis can be restricted to only those
individuals with complete data. This approach is
not optimal in terms of efficiency and is biased
in some situations. A second approach involves
imputing or ascribing values for the missing
values and then analyzing the revised dataset.
There are sophisticated procedures and software
packages available for this imputation and
subsequent analysis. This analysis can be biased
and can artifically improve precision. A third
approach involves analyzing the incomplete
dataset (i.e., without attempting to impute
values for the missing data).
Statistical techniques and associated
computer software (e.g., mixed models) exist
that take advantage of all available data and
minimize bias that are associated with analysis
restricted to only individuals with complete data
or analysis of imputed data. These techniques,
however, require assumptions about the nonresponse or the missing data mechanisms. If
these assumptions are incorrect, these models
can also produce biased results.
The most appropriate analytic techniques in
the presence of missing data are those closely
tied to the underlying missing data mechanism.
When the missingness does not depend on the
value of the complete or missing outcome, the
data are said to be missing completely at
random. Data are missing completely at random
if the probability of observing a missing value
does not depend on current or future data. For
example, if a data monitor forgets to ask a
patient if he or she has persistent chest pains
(angina) the missingness has nothing to do with
this subject’s cardiovascular health. A less strict
assumption about the missing data mechanism
is one in which the missingness is related only
to the data observed (and not related to
unmeasured or missing data).
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This missing data mechanism is called
missing at random and the probability of
observing a missing value depends on past data
but does not depend on current or future data.
For example, missing at random results when
missingness is related to past cardiovascular
health but is independent of unavailable current
or future cardiovascular health. Data that are
missing completely at random or missing at
random are said to be ignorable and to produce
a valid analysis it is not necessary to model the
missing data mechanism explicitly. Appropriate
analysis that include variables related to the
mechanism for missingness produce unbiased
results.
The final classification of missing data
mechanisms is called nonignorable missingness.
If the probability of observing a missing value
depends on unmeasured current and future data,
the missingness is nonignorable. An example
would be a subject who fails to show up for an
evaluation because his/her health has started to
deteriorate. The deterioration continues, and if
outcomes were measured, they would reflect the
decline. When missing data are nonignorable, it
is critical to model the missing data mechansim
explicitly in statistical models otherwise results
will be biased.
Even with these classifications for missing
data and the available statistical techniques and
software, there is no formal means to test which
mechanism is operating in a given situation. The
validity of the analysis often depends heavily
upon the assumptions of the technique.
Therefore, analysis and interpretation of results
in the presence of missing data are often open to
criticism. The best recommedation for handling
missing data is to avoid it wherever possible.
4. Analytic Techniques for Chronic Disease
Modeling
After the sample is selected and the risk
factors, the outcomes and the sampling
schedule determined, mathematical/statistical
modeling is needed to tie these together.
Several analytic techniques can be applied to
investigate this relation of the risk factors to
the development and progression of chronic
disease. Some of these are designed
specifically to relate baseline risk factors to
disease development. Some are able to exploit
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the time dependent nature of the risk factors
and the outcome events. We now describe
some popular techniques.
4.1
Logistic
Regression
Analysis:
Dichotomous Outcome
Logistic regression analysis can examine
and quantify the effects of risk factors on the
development of disease. The outcome of
interest is dichotomous (e.g., development or
non-development of chronic disease over a
time period), and the independent variables or
risk factors can include continuous or discrete
characteristics. The logistic regression model
is of the form:

 p 
 = α + β1 x 1 + β1 x 1 + ... + β p x p
ln
1
−
p


where Y is a dichotomous outcome variable
(e.g., 0=no chronic disease, 1=chronic disease)
and p=P(Y=1) is the probability of a subject
with the disease, x1, x2, …, xp are the risk
factors, and β1, β2,…βp are the regression
parameters reflecting how the risk factors
affect the log of the odds of developing
disease. Logistic regression analysis is a very
useful technique for analyzing dichotomous
outcomes and the individual is considered the
unit of analysis.
Logistic regression analysis is appropriate
in studies of chronic disease where originally
disease free subjects are followed for a prespecified observation period and at the end of
the observation period, each subject can be
classified as having developed the disease or
not. In many studies of chronic disease, there
are often have a number of individuals for
whom we do not have data at the end of the
observation period and the last time they were
observed they had not yet developed disease.
Logistic regression can not deal directly with
these subjects. The analysts must arbitrarily
drop them from analyses or assume a disease
status at the end of the observation period.
The techniques described in the next section
can handle this and other issues that arise in
longitudinal studies of chronic disease.
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4.2 Survival Analysis: Time to Event Data
Survival analysis includes a set of
techniques that deal with time until the event
of interest occurs (e.g., onset of disease). It is
often the case in studies of chronic disease that
there are many patients who do not develop
the disease or for whom we do not know if
they ever develop the disease. This happens
when the disease is rare, when patients are lost
to follow-up (e.g., move away but do not
develop the disease), when patients die during
the observation period but are free of the
disease of interest at the time of death, or
when they drop out of the study (e.g., due to
lack of interest).
In all of these situations, we do not have
the time to the development of disease.
However, these individuals can contribute a
substantial amount of information (up to the
end of the observed time period when we
know they are disease free) – information
which can be utilized through survival analytic
techniques. It is this aspect of the data that
distinguish survival analysis techniques from
other statistical techniques.
These observations in which we know the
individual is disease free for some period of
time, but do not know if they developed the
disease in other time periods are called
censored observations. There are several
different types of censoring, the most common
in studies of chronic disease is right censoring.
Right censored obervations are observations in
which we do not observe the time to event
because if it occurs it occurs after the last
observation point.
Some survival models are based on
parametric assumptions about the distribution
of the survival function, while others are not
(parametric and nonparameteric models,
respectively). A useful method to characterize
survival is by the hazard function (the
instantaneous rate of developing disease).
There are a number of popular parametric
survival models. The exponential model is
perhaps the simplest, but assumes constant
hazard over time and is therefore not generally
applied to chronic disease data. The Weibull
distribution model is a generalization of the
exponential model and is popular for
analyzing chronic disease risk (e.g., cancer

risk) and the hazard function is given by the
following:

h(t) = λγt γ −1
where λ=-ln(p)/t and p=P(disease free at time
t). The hazard at time t, h(t), increases as t
increases for γ>1 and decreases as t increases
if 0<γ<1. The exponential model is a special
case of the Weibull model with γ=1 (constant
risk with time).
Survival analysis methods can be used to
assess the effects of risk factors on the
development of chronic disease. There are
several models that are appropriate for this
purpose. A popular parametric model for
analysis of chronic disease is the accelerated
failure time model whose hazard function is

h(t) = e β'X h 0 (e β'x t)
where t reflects the time until disease onset,
h0(t) is the baseline hazard at time t (i.e., the
hazard if all of the risk factors were set to
zero), β'x=β1x1 + β2x2 + . . . + βpxp, x1, x2,

…, xp are the risk factors, and β1, β2,…βp

are the regression parameters.
A popular “nonparametric” survival
analysis model is the proportional hazards
model (also called the Cox regression model),
and it is commonly used to assess the relative
impact of a set of risk factors measured at a
point in time (baseline) on survival and
assumes that additive differences in risk
factors are related to multiplicative changes in
the hazard function.
The proportional hazards model can also
be used to assess the impact of time-dependent
covariates (i.e., risk factors that change over
time) on the hazard function and on survival.
This is a particularly useful feature of the
model in studies of chronic disease as
individuals may undergo procedures during
the observation period which alter their
prognosis. For example, an individual’s risk
of cardiovascular disease may change after
undergoing coronary artery bypass surgery.
The form of the Cox model is:

CHRONIC DISEASE DATA AND ANALYSIS

h(t) = h 0 (t)exp(β 1 x 1 + β 2 x 2 + ... + β p x p )
where h(t) is the hazard at time t, h0(t) is the
baseline hazard at time t (i.e., the hazard if all
of the risk factors were set to zero), and as
above x1, x2, …, xp are the risk factors, β1,
β2,…βp are the regression parameters
reflecting how the risk factors affect the
hazard. The risk factors, xi above, can be
variables measured at some baseline period or
variables that vary over time (called time
dependent variables).The proportional hazards
model is actually a semi-parametric model
because the distribution of the underlying
hazard is not specified.
Estimating the risk of developing chronic
disease per se or assessing the effects of a set
of risk factors on the development of chronic
disease may be complicated by a common
situation in studies of chronic disease, namely,
the competing risk of other diseases or death.
For example, in studying the relation of risk
factors to the development of coronary heart
disease the competing risk of someone
developing stroke needs to be considered.
Similarly, in examining the relation of
cigarette smoking to lung cancer the
competing risk of developing a heart attack
before the lung cancer is a real possibility.
Recently, there have been major efforts
to estimate the lifetime risk of developing
chronic diseases such as breast cancer,
coronary heart disease and Alzheimer’s
disease. A major methodological issue
involves the handling of death which can
occur before the chronic disease, such as
Alzheimer’s disease, develops.
4.3 Longitudinal Data Analysis: Mixed
Models, Generalized Linear Models and
Generalized Estimating Estimating Equations
A key feature of chronic disease data is
the repeated aspect of the measurements. In
longitudinal
studies
with
multiple
measurements taken on a set of individuals
over time, analytic techniques must take into
account the correlation between measurements
taken on the same individual. An added
complexity is the unbalanced nature of the
data due to different numbers of
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measurements taken on different subjects. We
now describe some popular methods for
analyzing incomplete longitudinal data; mixed
models and generalized estimating equations.
Mixed models procedures assume that
measurements taken over time are correlated
and that regression coefficients vary randomly
across subjects according to a specified
distribution. In these applications, some of the
effects are modeled as fixed (e.g., the effects
of risk factors on outcome, called within
subjects effects) and some as random
(between subject effects). These mixed effects
models are also referred to as random
coefficients models, growth curve models or
hierarchical models. They can also be
extended to incorporate time-dependent
covariates.
In these mixed effects models a parametric
structure is assumed also for the covariances
of the repeated measurements. There are many
distinct structures that can be assumed,
including the independence structure (all
observations are independent), compound
symmetry (the correlation between any two
observations is equal to some common value),
autoregressive,
and
unstructured
(no
specification of the structure of the
correlations).
Currently available statistical computing
packages offer many of these structures as
options in their mixed models applications.
Estimates of the fixed effects and the
covariances of the random effects can be
estimated using maximum likelihood using
Newton-Raphson
techniques
or
the
Expectation Maximization (EM) algorithm.
The estimates of the covariances are biased
because they do not take into account the
estimation of the fixed effects and therefore it
is recommended that these be estimated using
restricted
maximum
likelihood
which
produces unbiased estimates. Estimates of the
standard errors of effects are robust for large
samples.
Mixed models are appealing models for
longitudinal data as they are flexible and
handle unbalanced data in a highly efficient
manner. It is important to note that these
models produce consistent estimates (unbiased
for large samples) only when data are missing
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at random or missing completely at random.
These models require careful specification of
the fixed and random effects and a covariance
structure. When appropriate specifications are
made, the final estimates of the fixed and
random effects, as well as the magnitude of
the variance components are statistically
correct and highly informative.
A generalized linear model is a model in
which a specific link function (e.g., binomial,
Poisson, Gamma) is specified to relate the
mean (or expected) value of the outcome to a
linear function of the risk factors. This has the
effect of transforming the data to a linear
model, but involves correct specification of
the link or distribution of the outcome
variable. Parameters of the model are
estimated through maximum likelihood. The
appropriateness of the estimates in a
generalized linear model are highly dependent
on the distributional assumptions.
Generalized estimating equations (GEE)
are used to analyze correlated data (e.g., data
measured on the same subject over time) that
could otherwise be analyzed using a
generalized linear model but require fewer
distributional assumptions than generalized
linear models, making them more appealing.
The method of estimation is an extension of
least squares.
Generalized estimating equations produce
consistent estimates (unbiased for large
samples) and robust standard errors for large
samples. Generalized estimating equations are
appropriate when interest lies in “marginal”
effects (i.e., effects averaged over all
individuals) rather than subject-specific
effects. The approach is now available in
many statistical computing packages and again
requires specification of a covariance
structure. It is appropriate under the
asusmption of data missing completely at
random.
4.4 Tree-Based Classification Methods
Still another set of techniques for relating
risk factors to development of chronic disease
are tree-based classification methods. These
include a number of applications which are
intuitively appealing, many of which are based

on a technique called binary recursive
partitioning.
In binary recursive partitioning, a dataset
is partitioned first into two distinct groups on
the basis of the risk factor that best
discriminates the groups in terms of disease
status (present or absent). The process is
recursive in that this partitioning continues
until pre-specified stopping criteria are met
(e.g., the final groups represent the last
statistically significant splits). The outcome of
these analyses is in the form of a clinical
prediction rule or algorithm that resembles a
tree where the branches represent splits on a
risk factor.
Figure 1 illustrates a simple tree where
there are two splits. The first split is on the
basis of age (over 65 years versus 65 years and
younger). A second split is made among those
65 years of age and younger on the basis of
systolic blood pressure (less than 130 mm Hg
versus 130 or more mm Hg). Persons over 65
years of age have a 25% probability of
developing coronary heart disease. Persons 65
years of age and younger with systolic blood
pressure less than 130 have a 1% probability
of developing CHD, while persons 65 years of
age and younger with systolic blood pressure
of 130 or more have a 20% probability of
developing CHD.
When the outcome is dichotomous
(presence or absence of chronic disease) the
rule can be used to classify patients, on the
basis of specific criteria, as likely or unlikely
to develop the disease. The criteria are based
on specific values of risk factors. These
models are particularly appealing to clinicians
as they mirror common practice. For example,
a physician might gather information from a
patient on his/her risk factors (e.g., systolic
blood pressure, smoking status, alcohol
consumption), and may conduct a series of
laboratory tests (e.g., total Cholesterol level,
HDL cholesterol, triglycerides). Based on this
information, the clinician can appeal to the
empirical tree-based prediction rule to classify
the subject as likely or not likely to develop
the disease. These methods can also be used to
estimate the probability that this patient will
develop chronic disease.

CHRONIC DISEASE DATA AND ANALYSIS
Figure 1.
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Tree-Based Classification Methods: Example of A Simple
Classification Tree for Coronary Heart Disease (CHD)
10% with CHD
Age > 65

Age < 65

25% with CHD

9% with CHD

Classify as High Risk
SBP < 130

SBP > 130

1% with CHD

20% with CHD

Classify as Low Risk

Classify as High Risk

also for acute and epidemic disease).
Longitudinal data will be available on many
subjects thereby allowing for more complete
investigations of risk factors and interactions
between risk factors.
Advances in statistical computing
software will also allow for the estimation of
more complex statistical models, not restricted
to those which assume linear associations
between risk factors and chronic disease.
Finally, as more data become available on
families, analysis of chronic disease will include
exploration of genetic factors on the
development and progression of disease.

4.5 Neural Networks
Neural network models are a large class of
elaborate mathematical techniques used for
developing prediction rules. They are now
becoming popular methods for predicting
chronic disease. They are very flexible
prediction models that can accommodate large
datasets (i.e., many risk factors and large
sample sizes) and more complex relationships
among the variables.
4.6 Model Building
All of the above methods often involve a
development phase and a validation phase.
Investigators split a dataset into two distinct
parts, one part is used for developing the
model and the other part is used to evaluate
how the model performs (the validation
phase).
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